[go: up one dir, main page]

WO2007034323A1 - Composition destinee a etre utilisee dans le traitement de la calvitie, l'eclaircissage et la perte de cheveux et procede associe - Google Patents

Composition destinee a etre utilisee dans le traitement de la calvitie, l'eclaircissage et la perte de cheveux et procede associe Download PDF

Info

Publication number
WO2007034323A1
WO2007034323A1 PCT/IB2006/002671 IB2006002671W WO2007034323A1 WO 2007034323 A1 WO2007034323 A1 WO 2007034323A1 IB 2006002671 W IB2006002671 W IB 2006002671W WO 2007034323 A1 WO2007034323 A1 WO 2007034323A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
approximately
vitamin
extract
balding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002671
Other languages
English (en)
Inventor
Gerry Dean Freundl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002522453A external-priority patent/CA2522453A1/fr
Application filed by Individual filed Critical Individual
Publication of WO2007034323A1 publication Critical patent/WO2007034323A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Definitions

  • TITLE COMPOSITION FOR USE IN TREATMENT OF HAIR BALDING, THINNING
  • the present invention relates to a composition for use in a nutritional product, dietary supplement, pharmaceutical compound, or food composition or for use as a food additive wherein such composition is used to treat hair loss, balding, and thinning problems safely, effectively, and naturally.
  • the composition combines an herbal extract component and a vitamin component.
  • the present invention also relates to a method of treatment for hair loss, balding, and thinning disorders or problems.
  • Hair is composed of the keratin protein. Each hair grows from a hair follicle. At the base of the hair follicle is dermal tissue containing a dermal papilla.
  • the dermal papilla contains a network of capillary blood vessels to remove waste and supply oxygen, energy and the amino acids needed for hair growth.
  • the dermal papilla is sensitive to hormones which can affect hair growth. Hair growth involves three stages: anagen, the period of active growth which lasts for 2 to 4 years; catagen, the period of breakdown and change; and telogen, the resting stage before resumption of growth which lasts for 2 to 4 months.
  • On average daily hair loss is between sixty and one hundred hairs, all of which are normally replaced by new hairs. If the hair loss is over one hundred hairs per day, then the hair loss will exceed replacement, and baldness and thinning may result.
  • Hair loss, balding, and thinning disorders and problems include: alopecia totalis; alopecia universalis; androgenetic alopecia (hereinafter "AGA"); traction alopecia; diffuse alopecia; cicatricial alopecia; alopecia senilis; alopecia adnata; alopecia follicularis; and alopecia neurotica.
  • Alopecia is the general term for baldness which can range from temporary to permanent, and thinning to complete baldness.
  • the causes of the abovementioned disorders and problems include heredity factors; ageing; hormonal imbalance; illness and infectious diseases; nervous disorders; toxic substances; injury and impairment; and severe radiation.
  • AGA is a natural hair loss commonly known as male pattern baldness. This type of hair loss is the most commonly suffered by men and can range from minimal to very extreme hair loss; although women can also suffer from this type of hair loss. AGA can begin from the late teens to old age and may develop over a few years or a long period of time.
  • Testosterone is a steroid made from cholesterol and primes hair follicles for hair growth.
  • DHT Dihydrotestosterone
  • a derivative is converted from testosterone by the enzyme 5 ⁇ -reductase and regulates linear hair growth in the follicles.
  • Hair follicles actively convert testosterone to DHT by the enzyme 5 ⁇ -reductase.
  • the hair follicles of men or women suffering from AGA have enhanced activity of the enzyme 5 ⁇ -reductase and therefore a greater production of DHT or a greater number of androgen receptors for DHT to attach.
  • the DHT is present in the surface sebum secreted by the man or woman on their scalp clogging the pores of the scalp and stifling hair follicle growth.
  • the DHT When a hair is shed the DHT will enter the hair follicle where that hair came from.
  • the DHT causes the hair root and follicle to miniaturize.
  • the miniaturization of the hair root and follicle shortens the growth phase and causes the next hair to grow in finer. Thereafter, the same process will be repeated but each time the hair root and follicle are miniaturized and degraded further and the next hair grows back even finer. Eventually this process will result in baldness.
  • Current treatments for AGA and other hair loss, balding, and thinning disorders or problems include the application of anti-androgens which reduce the production of DHT by inhibiting the activity of 5 ⁇ -reductase; formulations which reduce the shrinking of the hair root and follicles; hair transplants; and wearing hairpieces. Additionally, current treatments for AGA include oral and topical treatments in a variety of dosage forms. Minoxidil is a current treatment for AGA and other hair loss, balding and thinning disorders or problems. Minoxidil is a topical product which requires two applications per day and is only for use by men.
  • Adverse side effects include rapid heart rate; unexplained weight gain; swelling or puffiness of the hands, face, ankles or stomach; dizziness, lightheadedness, or fainting; blurred vision; pain in the chest, arm, or shoulder; severe indigestion; and severe scalp irritation.
  • Finasteride is another current treatment for AGA and other hair loss, balding and thinning disorders or problems which inhibits 5 ⁇ -reductase activity.
  • Finasteride is a prescription product which is only for use by men. Finasteride has adverse side effects such as damaging the sex organs of unborn male babies when pregnant women accidentally ingest or handle the active ingredient of the product; affecting the efficacy of a blood test for prostate cancer; causing breast lumps, breast enlargement, nipple pain or tenderness, and nipple discharge in men; and creating hypersensitivity reactions including rash, pruritus, swelling of the lips and face and testicular pain.
  • AGA and other hair loss, balding, and thinning disorders or problems is a composition of liposterolic extract from saw palmetto and B-sitosterol. Additionally, the current treatments for AGA and other hair loss, balding, and thinning disorders or problems are only single medicinal ingredients and sometimes require a prescription. In view of the above, there is a need or a desire for a composition for the treatment of
  • AGA and other hair loss, balding, and thinning disorders or problems including all natural and botanical ingredients, such as herbal extracts and vitamins.
  • compositions which are generally well tolerated, without adverse side effects and beneficial to the overall health of the person being treated in addition to treating AGA and other hair loss, balding, and thinning disorders or problems.
  • compositions to treat AGA and other hair loss, balding, and thinning disorders or problems which involves multiple natural, active components, such as various herbal extracts and vitamins, which work synergistically together to provide overall 5 ⁇ - reductase activity; reduce excess cholesterol and testosterone resulting in less DHT production; and supporting the growth of strong, healthy looking hair.
  • compositions for use in a nutritional product, dietary supplement, pharmaceutical compound, or food composition or for use as a food additive wherein such composition is used to treat hair loss, balding, and thinning problems safely, effectively, and naturally has been developed.
  • the composition of the present invention combines an herbal extract component and a vitamin component.
  • the present invention also relates to a method of treatment for hair loss, balding, and thinning disorders or problems.
  • a general object of the present invention is to provide a natural, effective, safe composition, without adverse side effects, to treat hair loss, balding, and thinning disorders or problems.
  • the herbal extract component of the present invention is designed to promote normal hair growth, to reduce hair falling out, and to reduce shrinkage of hair follicles.
  • the vitamin component of the present invention is designed to promote normal hair growth, tissue formation, and general good health and to help metabolize the herbal components to make them more bio- available.
  • a more particularized object of the present invention is to provide a composition for the treatment of AGA.
  • Another object of the present invention is to provide a natural, effective, safe composition to treat hair loss, balding, and thinning disorders or problems wherein the herbal extract component and the vitamin component work synergistically together.
  • a further object of the present invention is to provide a composition to treat hair loss, balding, and thinning disorders or problems wherein 5 ⁇ -reductase activity and the conversion of cholesterol into DHT are inhibited.
  • An even further object of the present invention is to provide a composition to treat hair loss, balding, and thinning disorders or problems wherein a prescription is not required, both men and women can use the composition, and the composition is relatively cost effective.
  • the present invention also relates to a method of treating hair balding, thinning and loss disorders or problems involving the administration of the composition of the present invention in a single oral daily dosage.
  • the present invention relates to a composition of an herbal extract component, and a vitamin component, for use in a nutritional product, dietary supplement, pharmaceutical compound, or food composition, or for use as a food additive and to treat hair loss, balding, and thinning problems safely, effectively, and naturally.
  • the present invention also relates to a method of treatment for hair loss, balding, and thinning disorders or problems.
  • the composition components have therapeutic properties which together treat common hair loss, balding, thinning problems including alopecia, and AGA, and other hair loss, balding, and thinning related problems.
  • the composition is designed to promote normal hair growth and general good health, to reduce hair falling out, to promote hair growth, to reduce shrinkage of hair follicles, and to inhibit 5 ⁇ -reductase activity and the production of DHT.
  • the composition is all natural and botanical, generally beneficial to the overall health of the person being treated, and provides both inhibition of 5 ⁇ -reductase activity and conversion of cholesterol into DHT; has minimal side effects; involves multiple natural components which work synergistically together; is for both men and women; involves only a single oral daily dosage; is relatively cost effective; and does not require a prescription.
  • the composition components can be included in any of their commonly available forms.
  • the herbal extract component may be fenugreek seed extract.
  • the fenugreek seed extract can be taken from the Trigonella foenum-graecum plant.
  • the fenugreek seed extract can be in approximately a 4:1 ratio wherein 4 kg of dried fenugreek seeds yields 1 kg of water or alcohol soluble powdered fenugreek seed extract.
  • Fenugreek seed extract can contain sterols, such as ⁇ -sitosterol. ⁇ -sitosterol is a plant sterol which inhibits 5 ⁇ -reductase activity.
  • Fenugreek seed extract and ⁇ -sitosterol act by inhibiting 5 ⁇ -reductase activity wherein the conversion of testosterone to DHT is inhibited, the binding of DHT to its cell receptors is inhibited, or the breakdown of DHT is promoted. Inhibiting 5 ⁇ -reductase activity reduces the shrinkage of hair follicles, hair falling out, thinning of hair growth, and balding caused by DHT.
  • Fenugreek seed extract can further contain steroid saponins, and sapogenins, specifically diosgenin, which reduce cholesterol and hormone levels, including extra plasma cholesterol, and testosterone. The reduction of cholesterol and testosterone levels reduces the amount of DHT produced since DHT is derived from cholesterol.
  • Fenugreek seed extract can further contain flavonoids which are also known to be potent inhibitors of 5 ⁇ -reductase activity.
  • Fenugreek seed extract can also contain alkaloids, specifically trigonelline and choline, which inhibit 5 ⁇ - reductase activity, vasodilate the blood vessels and allow increased blood flow to the hair follicles.
  • fenugreek seeds can contain high amounts of protein necessary for cell growth, maintenance and repair, specifically hair growth and repair.
  • the herbal extract component can be lignans.
  • Lignans are phytoestrogens which are found in grains, legumes, vegetables, and fruits and are produced naturally in the human body.
  • the lignans can be taken from the flax plant (Linum usitatissimuni).
  • Flax lignans are similar to mammalian lignans and when supplemented to the human body can be normally metabolized by the human body.
  • lignans in flaxseed can include, but are not limited to, secoisolariciresinol-diglucoside (“SDG”) and enterolactone and enterodiol which are produced from flaxseed by the body.
  • SDG secoisolariciresinol-diglucoside
  • SDG contains 75 to 800 times more lignans than lignans taken from other plant sources.
  • the flaxseed lignans can contain approximately 20% SDG.
  • Lignans act by inhibiting 5 ⁇ -reductase activity wherein the conversion of testosterone to DHT is inhibited, the binding of DHT to its cell receptors is inhibited, or the breakdown of DHT is promoted. Inhibiting 5 ⁇ -reductase activity reduces the shrinkage of hair follicles, hair falling out, thinning of hair growth, and balding caused by DHT. Additionally, lignans from flaxseed are antioxidants which strengthen and promote a healthy immune system.
  • the herbal extract component may be saw palmetto (Serenoa repens) berry extract.
  • the saw palmetto berry extract is a lipophilic extract which can contain fatty acids, esters and sterols.
  • the saw palmetto berry extract can contain approximately 85-95% fatty acids, esters, and sterols.
  • the saw palmetto berry extract can contain approximately at least 45% fatty acids.
  • the saw palmetto berry extract acts by inhibiting 5 ⁇ -reductase activity wherein the conversion of testosterone to DHT is inhibited, the binding of DHT to its cell receptors is inhibited, or the breakdown of DHT is promoted. Inhibiting 5 ⁇ -reductase activity reduces the shrinkage of hair follicles, hair falling out, thinning of hair growth, and balding caused by DHT.
  • the vitamin component may be at least one of the following: biotin; vitamin B 5 (D-pantothenic acid); vitamin B 3 (nicotinamide); vitamin B 6 (pyridoxine HCL); vitamin B 2 (riboflavin); and folic acid.
  • Biotin is a B-complex vitamin and assists in the treatment of hair loss, balding, and thinning disorders and problems by promoting overall good health, and metabolizing fats and carbohydrates, including those contained in fenugreek seed, saw palmetto, and flax lignan extracts.
  • the vitamin B 5 can be calcium d-pantothenate and promotes overall good health and helps in tissue formation.
  • the vitamin B 3 can be nicotinamide and promotes overall good health and assists in normal growth and development.
  • the vitamin B 6 promotes overall good health and helps in tissue formation.
  • the vitamin B 2 promotes overall good health and helps in tissue formation, including hair tissue.
  • Folic acid is a B- vitamin and helps to maintain overall good health and to produce red blood cells.
  • the composition includes an herbal component and a vitamin component, the formulation including at least one or more of the following ingredients:
  • the composition includes an herbal component and a vitamin component, the formulation including at least one or more of the following ingredients in ranges of amounts which represent a daily therapeutic administration of the composition as follows: approximately 104 mg to 520 mg of Fenugreek seed extract; approximately 40 mg to 200 mg of Flax lignans; approximately 64 mg to 320 mg of Saw palmetto berry extract; approximately 160 meg to 800 meg of Bio tin; approximately 4 mg to 20 mg of Calcium D-pantothenic acid; approximately 4 mg to 20 mg of Nicotinamide; approximately 0.8 mg to 4 mg of Pyridoxine HCL; approximately 0.6 mg to 3 mg of Riboflavin; and approximately 0.04 mg to 0.2 mg of Folic acid.
  • the composition includes an herbal component and a vitamin component, the formulation including at least one or more of the following ingredients in amounts which represent a daily therapeutic administration of the composition as follows: approximately 260 mg of Fenugreek seed extract; approximately 100 mg of Flax lignans; approximately 160 mg of Saw palmetto berry extract; approximately 400 meg of Biotin; approximately 10 mg of Calcium D-pantothenic acid; approximately 10 mg of Nicotinamide; approximately 2 mg of Pyridoxine HCL; approximately 1.5 mg of Riboflavin; and approximately 0.1 mg of Folic acid.
  • the present invention also relates to a method of treating hair loss, balding, and thinning disorders or problems involving the administration of the composition of the present invention.
  • the administered composition of the present invention can be in any suitable oral form including, but not limited to, a capsule, tablet, powder, gel, or liquid.
  • the administration of the composition of the present invention can be an oral capsule taken in a single daily dose.
  • the administered composition of the present invention can be a food product, drug, functional food, food additive, beverage, dietary supplement or pharmaceutical compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention a trait à une composition pour le traitement de l'alopécie androgénique et d'autres troubles ou problèmes de calvitie, de perte et d'éclaircissage de cheveux, comportant un constituant d'extrait d'herbes et un constituant de vitamine. La présente invention a également trait à une composition pour le traitement de troubles ou problèmes de calvitie, de perte et d'éclaircissage de cheveux comportant un extrait de graine de fenugrec, du lignans du lin, un extrait de baie de chou palmiste nain, de la biotine de l'acide d-pantothénique, de la nicotinamide, de la pyridoxine HCL, de la riboflavine et de l'acide folique. La présente invention a trait en outre à un procédé pour le traitement de troubles ou problèmes de calvitie, de perte et d'éclaircissage de cheveux comprenant l'administration d'une composition en un unique dosage oral quotidien, ladite composition comportant un constituant d'extrait d'herbes et un constituant de vitamine et ladite composition étant inhibitrice de l'activité de 5α-réductase.
PCT/IB2006/002671 2005-09-26 2006-09-26 Composition destinee a etre utilisee dans le traitement de la calvitie, l'eclaircissage et la perte de cheveux et procede associe Ceased WO2007034323A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72052505P 2005-09-26 2005-09-26
US60/720,525 2005-09-26
CA002522453A CA2522453A1 (fr) 2005-09-26 2005-10-06 Composition et methode pour le traitement de la calvitie
CA2,522,453 2005-10-06

Publications (1)

Publication Number Publication Date
WO2007034323A1 true WO2007034323A1 (fr) 2007-03-29

Family

ID=37888588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002671 Ceased WO2007034323A1 (fr) 2005-09-26 2006-09-26 Composition destinee a etre utilisee dans le traitement de la calvitie, l'eclaircissage et la perte de cheveux et procede associe

Country Status (1)

Country Link
WO (1) WO2007034323A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104062372A (zh) * 2014-06-24 2014-09-24 成都合盛生物技术有限公司 一种胡芦巴总皂苷提取物的质量检测方法
EP3763226A1 (fr) 2019-07-12 2021-01-13 Merz Pharma GmbH & Co. KGaA Composition permettant de réduire la perte de cheveux et d'améliorer la croissance des cheveux en cas d'alopécie androgénétique
US11357751B2 (en) * 2016-05-23 2022-06-14 Attest Research Sdn Bhd Composition for preventing or mitigating dementia
EP4201418A1 (fr) 2021-12-23 2023-06-28 ASC Regenity Ltd. Composition de supplément nutritionnel de soins capillaires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030152655A1 (en) * 2000-02-09 2003-08-14 Burkhard Grallert Method and composition for promoting hair growth
US20040213859A1 (en) * 1999-09-17 2004-10-28 Zelickson Brian D. Organic nutrient for hair loss treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213859A1 (en) * 1999-09-17 2004-10-28 Zelickson Brian D. Organic nutrient for hair loss treatment
US20030152655A1 (en) * 2000-02-09 2003-08-14 Burkhard Grallert Method and composition for promoting hair growth

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Vitamin given as ingredient of Arcon tisane", Retrieved from the Internet <URL:http://www.n-e.co.uk/csp/gsh/ne/default.htm> *
ARCON TISANE: "Saw palmetto at caviar prices", HAIRSITE, 11 February 2007 (2007-02-11), XP003012710, Retrieved from the Internet <URL:http://www.hairsite2.com/library/abst-149.htm> *
DE JONG L: "The surprising health benefits of flax lignans", AGRO FOOD UNDUSTRY HI-TECH, vol. 15, no. 3, 2004, pages 5 - 7 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104062372A (zh) * 2014-06-24 2014-09-24 成都合盛生物技术有限公司 一种胡芦巴总皂苷提取物的质量检测方法
CN104062372B (zh) * 2014-06-24 2016-03-30 成都合盛生物技术有限公司 一种胡芦巴总皂苷提取物的质量检测方法
US11357751B2 (en) * 2016-05-23 2022-06-14 Attest Research Sdn Bhd Composition for preventing or mitigating dementia
EP3763226A1 (fr) 2019-07-12 2021-01-13 Merz Pharma GmbH & Co. KGaA Composition permettant de réduire la perte de cheveux et d'améliorer la croissance des cheveux en cas d'alopécie androgénétique
EP4201418A1 (fr) 2021-12-23 2023-06-28 ASC Regenity Ltd. Composition de supplément nutritionnel de soins capillaires
WO2023118518A1 (fr) 2021-12-23 2023-06-29 ASC REGENITY Limited Composition de complément nutritionnel pour soin capillaire

Similar Documents

Publication Publication Date Title
US8232317B2 (en) Method for increasing hair growth
US8440239B2 (en) Formulations and treatments for trichology
US8475849B2 (en) Formulations and treatments for well-being
KR20140107010A (ko) 발모 촉진용 조성물
US7713557B2 (en) Natural oriental medicinal composition for the promotion of hair growth and method of preparing the same
US20060110475A1 (en) Composition containing in combination at least one bourd oil and at least one borage oil, use thereof as medicine, as dermatological or dermato-cosmetic agent
KR100970126B1 (ko) 탈모방지 및 발모촉진용 조성물의 제조방법
WO2016199147A1 (fr) Composition pour le traitement de la chute des cheveux et la stimulation de la repousse
WO2007034323A1 (fr) Composition destinee a etre utilisee dans le traitement de la calvitie, l&#39;eclaircissage et la perte de cheveux et procede associe
KR20030062605A (ko) 자연 발효 추출물을 함유하는 탈모방지, 비듬방지 및모발성장 조성물
CA2522453A1 (fr) Composition et methode pour le traitement de la calvitie
US20070184003A1 (en) Apparatus and method for optimizing hair growth
KR20100060754A (ko) 경피 흡수를 통한 모발 성장 촉진용 외용제 조성물
DE202007012586U1 (de) Bockshornkleesamenextrakt
US20060073224A1 (en) Method of preparing Dioscorea tincture and uses thereof
JP7591492B2 (ja) ヘアケアの分野において使用するためのレスペデザ・カピタータ抽出物
KR20120046564A (ko) 천련자 추출물을 유효성분으로 함유하는 발모 및 두피 관리용 조성물
US8512772B1 (en) Dietary supplement for promotion of hair pigment restoration
KR100308491B1 (ko) 모발 성장 조성물
CN111713623A (zh) 一种固体饮料及其制备方法
KR20080011970A (ko) 푸에라리아 속 식물추출물을 함유하는 탈모방지 또는발모촉진용 조성물
WO2025215655A1 (fr) Kit pour favoriser la pousse des cheveux
AU2012202194B2 (en) Formulations and treatments for well-being
Goudar et al. Evaluation of choice of medicine for hair growth in practising hair implant surgeons-original research
HK1118012A (en) Formula ions and treatments for well-being

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06808898

Country of ref document: EP

Kind code of ref document: A1